Abstract:Overexpression of human epidermal growth factor receptor 2 (HER2) plays important roles in tumorigenesis and tumor progression in breast cancer. Nuclear imaging of HER2 expression in tumors might detect all HER2-positive tumors throughout the body and guide HER2-targeted therapies for patients. We therefore aimed to develop a HER2-targeted peptide probe for breast cancer imaging. A novel SPECT imaging probe, Tc-99m-HYNIC-H6F, was prepared and then evaluated in breast cancer animal models. Methods: The HER2-targeted peptide H6F (YLFFVFER) was conjugated with the bifunctional chelator hydrazinonicotinamide (HYNIC). Tc-99m-HYNIC-H6F was prepared, and the in vivo characteristics of Tc-99m-HYNIC-H6F were investigated in MDA-MB-453 (HER2-positive) and MDA-MB-231 (HER2-negative) models using small-animal SPECT/CT. Moreover, to investigate the specificity of the H6F peptide toward HER2 and the potential applications in monitoring therapies involving trastuzumab, unlabeled H6F and trastuzumab were used as blocking agents in cell competition studies and SPECT imaging. Results: A standard tricine/trisodium triphenylphosphine-3,3',3 ''-trisulfonate labeling procedure demonstrated that the radiochemical purity was greater than 95%. Tc-99m-HYNIC-H6F displayed excellent HER2-binding specificity both in vitro and in vivo. SPECT/CT imaging revealed that the MDA-MB-453 tumors were clearly visualized (percentage injected dose per gram, 3.58 +/- 0.01 at 30 min after injection), whereas the signals in HER2-negative MDA-MB-231 tumors were much lower (0.73 +/- 0.22 at 30 min after injection). Tumor uptake of MDA-MB-453 was blocked by the coinjection of excess H6F but not by excess trastuzumab. Conclusion: The Tc-99m-HYNIC-H6F peptide probe specifically accumulates in HER2-positive tumors and is therefore promising for the diagnosis of HER2-positive cancers. Because (99m)-HYNIC-H6F and trastuzumab target different regions of the HER2 receptor, this radiotracer also has great potential for monitoring the therapeutic efficacy of trastuzumab by rechecking the expression level of HER2 without blocking effect during therapy.

Development of a Novel HER2-Targeted Peptide Probe for Dual-Modal Imaging of Tumors

Functionalized NIR-II Semiconducting Polymer Nanoparticles for Single-cell to Whole-Organ Imaging of PSMA-Positive Prostate Cancer.

Novel Dual-Function Near-Infrared II Fluorescence and PET Probe for Tumor Delineation and Image-Guided Surgery.

A Novel TMTP1-modified Theranostic Nanoplatform for Targeted in Vivo NIR-II Fluorescence Imaging-guided Chemotherapy of Cervical Cancer

Radiolabeled AIE Probes As Dual-modality Imaging Agents for PET/NIR-II Fluorescence-Guided Photothermal Therapy

A novel near-infrared theranostic probe for accurate cancer chemotherapy <i>in vivo</i> by a dual activation strategy

Recent Development on Peptide-Based Probes for Multifunctional Biomedical Imaging

SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe 99Mtc-Hynic-h6f in Breast Cancer Mouse Models.

Her2 Targeting Peptides Screening And Applications In Tumor Imaging And Drug Delivery

A Novel Αvβ3 Integrin-Targeted NIR-II Nanoprobe for Multimodal Imaging-Guided Photothermal Therapy of Tumors in Vivo

Synergetic Tumor Probes for Facilitating Therapeutic Delivery by Combined-Functionalized Peptide Ligands

Hybridization of tumor homing and mitochondria-targeting peptide domains to design novel dual-imaging self-assembled peptide nanoparticles for theranostic applications

NAD(P)H-triggered Probe for Dual-Modal Imaging During Energy Metabolism and Novel Strategy of Enhanced Photothermal Therapy in Tumor.

Dual-Targeted Molecular Probes for Cancer Imaging

Targeting HER2-positive Gastric Cancer with a Novel 18F-Labeled ZHER2:342 Probe

Microarray Based Screening of Peptide Nano Probes for HER2 Positive Tumor.

PET/NIR Fluorescence Bimodal Imaging for Targeted Tumor Detection

Development of Gold Nanorods Conjugated with Radiolabeled Anti-human Epidermal Growth Factor Receptor 2 (HER2) Monoclonal Antibody As Single-Photon Emission Computed Tomography/Photoacoustic Dual-Imaging Probes Targeting HER2-Positive Tumors.

Developing PEGylated Reversed D-Peptide As a Novel HER2-Targeted SPECT Imaging Probe for Breast Cancer Detection

A PD-L1-Targeted Probe Cy5.5-A11 for In Vivo Imaging of Multiple Tumors

Biosynthetic molecular imaging probe for tumor-targeted dual-modal fluorescence/magnetic resonance imaging